These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 19358301)

  • 1. FAK silencing inhibits leukemogenesis in BCR/ABL-transformed hematopoietic cells.
    Le Y; Xu L; Lu J; Fang J; Nardi V; Chai L; Silberstein LE
    Am J Hematol; 2009 May; 84(5):273-8. PubMed ID: 19358301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overexpression or knock-down of runt-related transcription factor 1 affects BCR-ABL-induced proliferation and migration in vitro and leukemogenesis in vivo in mice.
    Yang LJ; Yu WD; DU JB; Chao S; Chen MX; Zhao HH; Guo JZ
    Chin Med J (Engl); 2009 Feb; 122(3):331-7. PubMed ID: 19236814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tyrosine phosphorylation and activation of focal adhesion kinase (p125FAK) by BCR-ABL oncoprotein.
    Gotoh A; Miyazawa K; Ohyashiki K; Tauchi T; Boswell HS; Broxmeyer HE; Toyama K
    Exp Hematol; 1995 Oct; 23(11):1153-9. PubMed ID: 7556524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cooperative and redundant effects of STAT5 and Ras signaling in BCR/ABL transformed hematopoietic cells.
    Hoover RR; Gerlach MJ; Koh EY; Daley GQ
    Oncogene; 2001 Sep; 20(41):5826-35. PubMed ID: 11593388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of p21(WAF1/CIP1) as an attenuator of both proliferative and drug-induced apoptotic signals in BCR-ABL-transformed hematopoietic cells.
    Forster K; Obermeier A; Mitina O; Simon N; Warmuth M; Krause G; Hallek M
    Ann Hematol; 2008 Mar; 87(3):183-93. PubMed ID: 17960378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Id1 transcription inhibitor-matrix metalloproteinase 9 axis enhances invasiveness of the breakpoint cluster region/abelson tyrosine kinase-transformed leukemia cells.
    Nieborowska-Skorska M; Hoser G; Rink L; Malecki M; Kossev P; Wasik MA; Skorski T
    Cancer Res; 2006 Apr; 66(8):4108-16. PubMed ID: 16618731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
    Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
    Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RNAi-mediated silencing of p190Bcr-Abl inactivates Stat5 and cooperates with imatinib mesylate and 17-allylamino-17-demetoxygeldanamycin in selective killing of p190Bcr-Abl-expressing leukemia cells.
    Futami M; Hatano T; Soda Y; Kobayashi S; Miyagishi M; Tojo A
    Leukemia; 2008 Jun; 22(6):1131-8. PubMed ID: 18368071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stable RNA interference (RNAi) as an option for anti-bcr-abl therapy.
    Scherr M; Battmer K; Schultheis B; Ganser A; Eder M
    Gene Ther; 2005 Jan; 12(1):12-21. PubMed ID: 15602589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tyrosine kinase modulation of protein kinase C activity regulates G protein-linked Ca2+ signaling in leukemic hematopoietic cells.
    Vichalkovski A; Kotevic I; Gebhardt N; Kaderli R; Porzig H
    Cell Calcium; 2006 Jun; 39(6):517-28. PubMed ID: 16620963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BCR/ABL inhibits mismatch repair to protect from apoptosis and induce point mutations.
    Stoklosa T; Poplawski T; Koptyra M; Nieborowska-Skorska M; Basak G; Slupianek A; Rayevskaya M; Seferynska I; Herrera L; Blasiak J; Skorski T
    Cancer Res; 2008 Apr; 68(8):2576-80. PubMed ID: 18413724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BCR/abl leads to the constitutive activation of Stat proteins, and shares an epitope with tyrosine phosphorylated Stats.
    Frank DA; Varticovski L
    Leukemia; 1996 Nov; 10(11):1724-30. PubMed ID: 8892675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.
    Kurosu T; Ohki M; Wu N; Kagechika H; Miura O
    Cancer Res; 2009 May; 69(9):3927-36. PubMed ID: 19366808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overexpression/enhanced kinase activity of BCR/ABL and altered expression of Notch1 induced acute leukemia in p210BCR/ABL transgenic mice.
    Mizuno T; Yamasaki N; Miyazaki K; Tazaki T; Koller R; Oda H; Honda ZI; Ochi M; Wolff L; Honda H
    Oncogene; 2008 May; 27(24):3465-74. PubMed ID: 18193087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Critical role for cyclin D2 in BCR/ABL-induced proliferation of hematopoietic cells.
    Jena N; Deng M; Sicinska E; Sicinski P; Daley GQ
    Cancer Res; 2002 Jan; 62(2):535-41. PubMed ID: 11809706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor growth inhibition by synthetic and expressed siRNA targeting focal adhesion kinase.
    Tsutsumi K; Kasaoka T; Park HM; Nishiyama H; Nakajima M; Honda T
    Int J Oncol; 2008 Jul; 33(1):215-24. PubMed ID: 18575768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The BCR-ABL tyrosine kinase inhibits apoptosis by activating a Ras-dependent signaling pathway.
    Cortez D; Stoica G; Pierce JH; Pendergast AM
    Oncogene; 1996 Dec; 13(12):2589-94. PubMed ID: 9000132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intrinsic FAK activity and Y925 phosphorylation facilitate an angiogenic switch in tumors.
    Mitra SK; Mikolon D; Molina JE; Hsia DA; Hanson DA; Chi A; Lim ST; Bernard-Trifilo JA; Ilic D; Stupack DG; Cheresh DA; Schlaepfer DD
    Oncogene; 2006 Sep; 25(44):5969-84. PubMed ID: 16682956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early events in leukemogenesis in P190Bcr-abl transgenic mice.
    Salloukh HF; Vowles I; Heisterkamp N; Groffen J; Laneuville P
    Oncogene; 2000 Sep; 19(38):4362-74. PubMed ID: 10980612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. N-acetyl cysteine enhances imatinib-induced apoptosis of Bcr-Abl+ cells by endothelial nitric oxide synthase-mediated production of nitric oxide.
    Rakshit S; Bagchi J; Mandal L; Paul K; Ganguly D; Bhattacharjee S; Ghosh M; Biswas N; Chaudhuri U; Bandyopadhyay S
    Apoptosis; 2009 Mar; 14(3):298-308. PubMed ID: 19153832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.